Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.50 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395813 | 0.85 | MAPT (0.40) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL2393730 | 0.79 | L3MBTL1 (0.43) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL2398766 | 0.74 | MAPT (0.43) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL16147635 | 0.73 | TP53 (0.51) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL14363618 | 0.72 | THRB (0.56) | LMNAHTTSMN1; SMN2RAB9ATP53 | |
| SCHEMBL15156985 | 0.70 | POLB (0.52) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL14556352 | 0.69 | TTR (0.51) | LMNAHPGDSMN1; SMN2RAB9ATP53 | |
| SCHEMBL14363636 | 0.68 | L3MBTL1 (0.62) | LMNASMN1; SMN2RAB9ATP53NPC1 | |
| SCHEMBL14810948 | 0.67 | PLK1 (0.47) | LMNAHTTHPGDSMN1; SMN2RAB9A | |
| SCHEMBL14363616 | 0.67 | L3MBTL1 (0.57) | SMN1; SMN2RAB9ATP53NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765768-B1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2013-11-06 | — | — | EP | disclosed |
| US-8022248-B2 | 3-[2-(3-Cyanophenoxy)-4-(trifluoromethyl)phenyl]propanoic acid;prostaglandin D2 inhibitor, orphan receptor CRTH2 antagonist; antiinflammatory, analgesic, antipyretic; respiratory system disorders: asthma and rhinitis; coupling amino/thio-phenyl derivatives with ester followed by hydrolysis to acid | ASTRAZENECA AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | ASTRAZENECA AB (SE) | 2008-05-15 | — | — | US | disclosed |
| EP-1765768-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | AstraZeneca AB (SE) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006005909-A1 | SUBSTITUTED ACIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114002-A1 | Substituted Acids for the Treatment of Respiratory Diseases | HRH2, HRH1, HRH4 | LMNA 1920/4885HTT 2006/4885HPGD 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.